cycloheptylhydrazile hydrochloride | 1258640-59-3

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: cycloheptylhydrazile hydrochloride
• 英文别名: cycloheptylhydrazine hydrochloride；cycloheptylhydrazine chloride；cycloheptylhydrazine;hydrochloride
• CAS: 1258640-59-3
• 化学式: C₇H₁₆N₂*ClH
• 分子量: 164.678
• InChiKey: IKKKEDGXOWBLHT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.59
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  38
• 氢给体数：
  3
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  cycloheptylhydrazile hydrochloride 在 N-溴代丁二酰亚胺(NBS) 、 sodium hydride 、 N,N-二异丙基乙胺 作用下， 以 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 0.66h， 生成 5-amino-1-cycloheptyl-3-(2-ethoxyquinolin-6-yl)-1H-pyrazole-4-carboxamide
  参考文献：
  名称：

  SAR Studies of 5-Aminopyrazole-4-carboxamide Analogues as Potent and Selective Inhibitors of Toxoplasma gondii CDPK1

  摘要：

  We previously discovered compounds based on a 5-aminopyrazole-4-carboxamide scaffold to be potent and selective inhibitors of CDPK1 from T. gondii. The current work, through structure-activity relationship studies, led to the discovery of compounds (34 and 35) with improved characteristics over the starting inhibitor 1 in terms of solubility, plasma exposure after oral administration in mice, or efficacy on parasite growth inhibition. Compounds 34 and 35 were further demonstrated to be more effective than 1 in a mouse infection model and markedly reduced the amount of T. gondii in the brain, spleen, and peritoneal fluid, and 35 given at 20 mg/kg eliminated T. gondii from the peritoneal fluid.

  DOI：

  10.1021/acsmedchemlett.5b00319
• 作为产物：
  描述：

  N'-cycloheptyl-hydrazinecarboxylic acid tert-butyl ester 在 盐酸 作用下， 以 四氢呋喃 为溶剂， 反应 0.17h， 生成 cycloheptylhydrazile hydrochloride
  参考文献：
  名称：

  High-yielding synthesis of monoalkylhydrazines

  摘要：

  DOI：

  10.1021/jo00339a035

文献信息

• A Variation of the Fischer Indolization Involving Condensation of Quinone Monoketals and Aliphatic Hydrazines
  作者：Jinzhu Zhang、Zhiwei Yin、Patrick Leonard、Jing Wu、Kate Sioson、Che Liu、Robert Lapo、Shengping Zheng

  DOI：10.1002/anie.201207533

  日期：2013.2.4

  new twist: A one‐pot nitrous acid free, diazonium‐free, and transition‐metal‐free variation of the Fischer indole synthesis has been developed. Condensation of quinone monoketals and aliphatic hydrazine hydrochlorides afforded indoles via intermediate alkylaryldiazenes. This method will complement the classical Fischer indole synthesis by providing indoles in two steps from widely available phenols

  一个新的转折：已开发出Fischer吲哚合成的一锅无亚硝酸，无重氮和无过渡金属的变体。醌单缩酮和脂族肼盐酸盐的缩合通过中间体烷基芳基二氮烯得​​到吲哚。该方法将在温和的条件下从两步制得的苯酚中分两步提供吲哚，从而补充了经典的Fischer吲哚合成方法。
• Synthesis, biological evaluation, and structural studies on N1 and C5 substituted cycloalkyl analogues of the pyrazole class of CB1 and CB2 ligands
  作者：Mathangi Krishnamurthy、Wei Li、Bob M Moore

  DOI：10.1016/j.bmc.2003.10.045

  日期：2004.1

  A series of N1 and C5 substituted cycloalkyl and C5 4-methylphenyl analogues of the N-(piperidin-1-yl)-4-methyl-1H-pyrazole-3-carboxamide class of cannabinoid ligands were synthesized. The analogues were evaluated for CB1 and CB2 receptor binding affinities and receptor subtype selectivity. The effects of pyrazole substitution on ligand conformation and as such receptor affinities was not readily apparent;

  合成了一系列大麻素配体的N-（哌啶-1-基）-4-甲基-1H-吡唑-3-羧酰胺类的N1和C5取代的环烷基和C5 4-甲基苯基类似物。评价类似物的CB1和CB2受体结合亲和力和受体亚型选择性。吡唑取代对配体构象及其受体亲和力的影响尚不十分清楚。因此，使用高场NMR光谱学和系统的分子力学几何搜索方法研究了N1和C5取代基相对于吡唑环的几何结构。相对环几何形状和官能团方向的分析提供了对CB1和CB2配体结合口袋的结构要求的新见解。
• Thienopyrazole Derivative Having PDE7 Inhibitory Activity
  申请人：Inoue Hidekazu

  公开号：US20090131413A1

  公开（公告）日：2009-05-21

  To provide thienopyrazole derivatives inhibiting PDE 7 selectively, and therefore, enhance cellular cAMP level. Consequently, the compound is useful for treating various kinds of disease such as allergic diseases, inflammatory diseases or immunologic diseases. The compound is thienopyrazole compound represented by the following formula (I): [wherein, especially, R 1 is a cyclohexyl, a cycloheptyl group or a tetrahydropyranyl group; R 2 is methyl; R 3 is a hydrogen atom; and R 4 is a group: —CONR 5 R 6 (in which any one of R 5 and R 6 is a hydrogen atom)].

  为了提供选择性抑制PDE 7的噻唑吡啶衍生物，从而增强细胞cAMP水平。因此，该化合物可用于治疗各种疾病，如过敏性疾病、炎症性疾病或免疫性疾病。该化合物是由以下式子(I)表示的噻唑吡啶化合物：[其中，特别地，R1是环己基、环庚基或四氢吡喃基；R2是甲基；R3是氢原子；R4是一个基团：—CONR5R6（其中R5和R6中的任何一个是氢原子）]。
• Thienopyrazole derivatives having PDE7 inhibitory activity
  申请人：Daiichi Sankyo Company, Limited

  公开号：EP2433943A1

  公开（公告）日：2012-03-28

  To provide thienopyrazole derivatives inhibiting PDE 7 selectively, and therefore, enhance cellular cAMP level. Consequently, the compound is useful for treating various kinds of disease such as allergic diseases, inflammatory diseases or immunologic diseases. The compound is thienopyrazole compound represented by the following formula (I): [wherein, especially, R1 is a cyclohexyl, a cycloheptyl group or a tetrahydropyranyl group; R2 is methyl; R3 is a hydrogen atom; and R4 is a group: -CONR5R6 (in which any one of R5 and R6 is a hydrogen atom)].

  提供选择性抑制 PDE 7 并因此提高细胞 cAMP 水平的噻吩并吡唑衍生物。因此，该化合物可用于治疗各种疾病，如过敏性疾病、炎症性疾病或免疫性疾病。该化合物是由下式（I）代表的噻吩并唑化合物： [其中，R1 特别是环己基、环庚基或四氢吡喃基；R2 是甲基；R3 是氢原子；R4 是基团：-CONR5R6（其中 R5 和 R6 中的任一个是氢原子）]。
• THIENOPYRAZOLE DERIVATIVE HAVING PDE7 INHIBITORY ACTIVITY
  申请人：Daiichi Sankyo Company, Limited

  公开号：EP1775298B1

  公开（公告）日：2013-03-20